Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Cardiologists who Specialize in Hypertension (US)

Council Members in this Study Group: 167

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Daniel Fisher

Cardiologist
NEW YORK UNIVERSITY (INC)
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology....

Dan Streja

Clinical Professor of Medicine
UNIVERSITY OF CALIFORNIA, LOS ANGELES
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA...

Joshua Feuer

Owner
JOSHUA M FEUER
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Joshua Feuer, MD, FACC, is a board certified Cardiologist in solo private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and...

Barry Massie, Chief of the Cardiology Division , San Francisco Veterans Affairs Medical CenterBarry Massie

Chief of the Cardiology Division
San Francisco Veterans Affairs Medical Center
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Barry Massie, MD, is the Professor of Medicine at the University of California, San Francisco and Chief of Cardiology at San Francisco VAMC. Dr. Massie is an expert in heart failure, hypertension, and cardiovascular therapeutics. He has authored over...

Robyn Barst, Former Director, NEW YORK PRESBYTERIAN & COLUMBIA MEDICAL CENTERRobyn Barst

Former Director
NEW YORK PRESBYTERIAN & COLUMBIA MEDICAL CENTER
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Robyn J Barst, MD is Professor Emeritus of Pediatrics (in Medicine) at the College of Physicians and Surgeons at Columbia University. She was Director of the New York-Presbyterian Pulmonary Hypertension Center 1982-2008. She is a Fellow of the American...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

If it seems too good to be true...it probably is.

December 9, 2008

Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com

This article implies that physician's have no justifiable reason for prescribing brand-name drugs. Unfortunately, it's not that simple.

“You've got to be very careful if you don't know where you are going, because you might not get there.” Yogi Berra

December 8, 2008

Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows | pharmalive.com

There is a question of bias in this study. It is not prospective, not randomized and not blinded and thus no valid conclusions can be made. The study should be ignored. It will have no impact on sales.

Outsourcing of compassionate use of drugs?

January 18, 2008

No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com

The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.  

Niacin...it's deja vu all over again.

January 29, 2007

An Old Cholesterol Remedy Is New Again | www.nytimes.com

1. Pfizer Inc, the pharmaceutical giant, halted late-stage trials of the HDL increasing drug torcetrapib after investigators discovered that it increased heart problems and increased death rates in the treated population.
2. Niacin, a B vitamin that increases HDL (the good cholesterol) up to 35%, has largely been ignored by physicians treating hypercholesterolemia and coronary heart disease because it is difficult to prescribe related to the common nuisance, but non-serious side effect of flushing.
3. Statins typically decrease LDL (the bad cholesterol) by 30-50% and cardiovascular events by about 30-40% but one analysis suggests that by decreasing LDL by 40% and increasing HDL by 30%, cardiovascular events could be decreased by 70%.
4. A large trial is underway to test this hypothesis comparing statin therapy alone with combination statin plus niacin therapy.

Drug-eluting Versus Uncoated Stents

September 19, 2006

NEJM Articles on DES in MI | content.nejm.org

The lead articles from the New England Journal of Medicine 9/14/06 reviewed new data showing benefits when comparing sirolimus-eluting stents to uncoated stents and when comparing paclitaxil eluting stents to uncoated stents.

There was a significant reduction in target-vessel revascularization at one year with the sirolimus-eluting stents compared to uncoated stents.

There was a trend (not statistically significant) toward reduction of serious adverse cardiac events at one year with paclitaxil-eluting stents compared to uncoated stents.

 

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Physician - Division Head
  • President
  • Partner

GLG Live Meetings with this Study Group's Leading Experts (?)

August 21, 2008 | Palo Alto

GLG Seminar: (Palo Alto) Heart Failure

March 2, 2006 | New York

GLGi: Cardiology Grand Rounds

GLG Webcasts & Teleconferences

Leading Experts in Cardiologists who Specialize in Hypertension (US) have not participated in any GLG webcasts.

View All GLG Webcasts & Teleconferences in Healthcare